COSMO Pharmaceuticals SA

Research COSMO Pharmaceuticals SA (0RGI) on Bullrun: P/E 50.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker0RGI
• ExchangeLSE
• CountryIreland
• SectorHealthcare
• IndustryDrug Manufacturers - General
• CurrencyGBP
• P/E50.2
• Financial periodFY2025
• RevenueGBP 104.17M
• Revenue growth-61.0%
• Net income-GBP 3.61M
• Free cash flow-GBP 17.95M
• Gross margin48.5%

Valuation Snapshot

P/E is 50.2.

About COSMO Pharmaceuticals SA

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris;

Frequently asked questions

What is COSMO Pharmaceuticals SA's P/E ratio?

COSMO Pharmaceuticals SA's price-to-earnings (P/E) ratio is 50.2.

What does COSMO Pharmaceuticals SA do?

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.